Most of the respondents in our survey preferred to use colistin-based combination therapy and intravenous antibiotics to treat VAP and VAT caused by XDR AB. However, colistin dose and duration varied among the healthcare providers.
M echanical ventilation is commonly used as a therapeutic option when caring for critically ill patients in the intensive care unit )ICU(. Although mechanical ventilation may be lifesaving, it is associated with an increased risk of infections, including ventilatorassociated pneumonia )VAP( and ventilator-associated tracheobronchitis )VAT(. Ventilator-associated pneumonia has an estimated incidences of 10-25% and VAT has 1.4-11% with an estimated all-cause mortality of 25-50% for VAP, and 39% for VAT. [1] [2] [3] Late-onset VAP )occurring after 5 days( is usually caused by multidrugresistant )MDR( organisms and is associated with an increase in morbidity and mortality. 1, 2 The increased incidence of infections with these MDR pathogens is a major concern to health care providers worldwide and in particular Acinetobacter species, which were recognized as a cause of infection in critically ill patients in the past decade. With an increase in the use of broad-spectrum antibiotics, MDR and extensively drug-resistant )XDR( Acinetobacter baumannii )AB( have emerged as common pathogens causing late-onset VAP in the Middle East and Europe. [4] [5] [6] The attributable mortality for ICU infected with AB was 10-43%, and for in-hospital patients )those who did not require ICU( was 8-23%. 7 These high rates are likely related to the limited number of drugs available to treat XDR strains, as AB has an exceptional pathogenicity and capability to develop inherent and acquired resistance. The current knowledge on its treatment is insufficient as the quality of evidence, and the clinical practice guidelines are lacking. There are many controversies regarding different treatment options such as the superiority of combination therapy over monotherapy and the optimal dose of colistin, which is usually the only antibiotic to which XDR AB is susceptible. 8, 9 These have led to a variation in practice. The objective of this study was to investigate the current practices of clinicians and clinical pharmacists )CPs( caring for patients with XDR AB infections in Saudi Arabia. A survey was conducted to find answers to the following questions: Is combination therapy superior to monotherapy? Is there any role for colistin nebulization? What is the optimal dose of colistin?.
Methods. This cross-sectional study was performed in tertiary-care centers of Saudi Arabia between March and June 2014. The PubMed database was used to find prior related research.
The study subjects were physicians who were specialized in infectious disease )ID(, critical care medicine, and clinical pharmacology in all major hospitals in different regions of Saudi Arabia. Informed consent was not required as the survey consisted of voluntary anonymous responses to a web-based questionnaire with no risk of breaching the participants' confidentiality.
The sample size calculation was not performed a priori as we aimed at surveying all the specified healthcare providers in Saudi Arabia that were accessible via emails or social networks. After personal communication with acquaintances in the target hospitals, snowball sampling was used to reach the target healthcare providers. Assuming that the number of healthcare providers who were the target for this survey was 300, a reasonable estimate, the calculated sample size would be 169 at 95% confidence interval and 5% margin of error.
Item generation and development of questions. Five experts )3 ICU and 2 ID physicians( generated items through group discussion. Multiple meetings and discussions were held to shorten the list of items to reduce the burden on respondents and minimize redundancy while retaining the important items. Questions were developed based on the items of interest and were structured as multiple-choice questions that allowed a single answer for each question. The questionnaire was piloted with 10 participants before it was finalized. Feedback was obtained on the clarity and terminology of questions, and the questions were adjusted according to the feedback received and then the questionnaire was retested by the same 10 participants.
The final questionnaire was administered in English and investigated 3 components: respondent characteristics, antibiotic choice for 3 different clinical scenarios )VAP, VAT, and septic shock( and the duration of therapy for each of the clinical scenarios. Respondent characteristics included the medical specialty, job title )consultant, or fellow/registrar(, and number of years practicing in that specialty. Questions regarding antibiotics, including the antibiotic preferred to treat VAP caused by XDR AB, monotherapy versus combination therapy, duration, dose )in patients with normal kidney function and in those with acute kidney injury [AKI](, treatment of VAT caused by XDR AB, and the route )intravenous versus nebulization( used to treat VAT. The questionnaire also contained questions to assess physician's specialty title, years of experience, level of care, and perceptions of current clinical practice.
Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company. Tables 1 & 2 . Most of the respondents were specialized in intensive care medicine )70.6%( followed by ID and clinical pharmacology )14.7% each(.
Responses of all study subjects. Most of the physicians )54.6%( preferred colistin-based combination therapy as the first-choice treatment for VAP caused by XDR AB. The remaining 45.4% believed that IV colistin alone was sufficient. Carbapenems were the most frequently preferred antibiotics in combination with colistin )26.8%( followed by tigecycline )16.4%(. Sixty-three percent of respondents believed that 2 weeks of therapy were sufficient for treating VAP caused by XDR AB ) Table 3 (. For VAT caused by XDR AB, 80% of respondents agreed that patients should be treated with antibiotics )p<0.0001(. Approximately 38% of respondents preferred to use 2 million units )mu( )160 mg( of colistin every 8 hours without a loading dose, whereas 35.8% chose a 9 mu )720 mg( loading dose of colistin, followed by 3 mu )240 mg( every 8 hours, or 4.5 mu )360 mg( every 12 hours to treat VAP caused by XDR AB )p<0.0001(. In case of AKI, 89.8 of respondents preferred to modify colistin dosing according to the creatinine clearance. When septic shock was present in patients with late-onset VAP on broad-spectrum antibiotics, most of the respondents )58.7%( preferred to add IV colistin empirically ) Table 3 (.
Responses according to position. Table 4 describes responses according to position. Most fellows )61% of ID and 58% of ICU( and ID consultants )55%( preferred combination therapy to treat VAP caused by XDR AB. Half of the ICU consultants and 52.4% of the CPs opted for IV colistin alone. Almost 41% of ICU fellows and 35% of CPs preferred to treat XDR AB VAP patients with normal renal function using 2 mu of colistin every 8 hours without a bolus dose. Most consultants )60% of ID and 45.8% of ICU( and ID fellows )44.4%( preferred to use a colistin loading dose of 9 mu followed by 3 mu every 8 hours, or 4.5 mu every 12 hours. Most CPs )66.7%(, ICU physicians )64.3%(, and ID physicians )57.8%( believed that a 2-week regimen was appropriate. When treating patients with late-onset VAP and shock despite broad-spectrum antibiotics, 80% of ID consultants recommended adding colistin empirically compared with 36.8% of CPs. Responses according to clinical experience. As described in Table 5 , more than 50% of the subjects at all experience levels preferred to treat patients with colistin for 14 days. From the subjects who had 5-10 years of experience, 38.3% favored using IV colistin alone to treat VAT while the respondents with more experience chose not to treat )33.3%(, or to treat with inhaled colistin alone )34.5%(. More than two-thirds of the subjects preferred using either 2 mu )160mg( every 8 hours without a loading dose, or a loading dose with a higher maintenance dose of intravenous colistin to treat patients with XDR AB VAP irrespective of the length of experience. For late-onset, VAP patients in shock despite broad-spectrum antibiotics, the empirical coverage recommendations were similar regardless of the length of experience.
Predictors of the prevalent management choices. As represented in Table 6 , IV colistin alone was the prevalent choice for VAP management. Healthcare practitioners at tertiary-care hospitals were more likely to choose this response compared with those working at other hospitals )OR=1.96; 95% CI: 1.07-5.58(. Specialty, job title, and the length of experience did not predict this response.
For VAP treatment duration, 14 days was the prevalent choice. None of the independent variables entered in the multivariate model predicted this response. Intravenous colistin alone was the prevalent choice for treatment of VAT. Being a consultant )OR=2.38; 95% CI: 1.03-5.49( and the length of experience more than or equal 10 years )OR=0.07; 95% CI: 0.02-0.26( were predictors of this response compared with healthcare practitioners of a different professional status and less experience.
Two million units )160 mg( of IV colistin every 8 hours without loading was the prevalent dose with creatinine clearance being more than or equal 70 ml/min. None of the independent variables entered in the multivariate model predicted this response. For AKI after IV colistin, modifying the colistin dose according to creatinine clearance was the prevalent choice. None of the independent variables entered in the multivariate model predicted this response. For septic shock not improving after 3 days of meropenem and vancomycin, "adding IV colistin" was the prevalent choice. The CP's were less likely to choose this response compared with ID physicians )OR=0.19; 95% CI: 0.05-0.66(. The other factors did not predict this response.
Discussion. The purpose of this survey was to assess current knowledge and practice among physicians and CPs in tertiary centers of Saudi Arabia. The main finding was that most respondents recommended for treating VAP caused by XDR AB with a combination of IV colistin and carbapenem for 2 weeks. Most respondents recommended using 2 mu of colistin every 8 hours, preceded by a loading dose, and 50% of participants opted for colistin therapy empirically when treating patients that had VAP and persistent septic shock while on broad-spectrum antibiotics. Most consultants preferred to treat VAT with IV colistin. In contrast, 38.1% of CPs and 33.3% of ID fellows preferred to use inhaled colistin alone. Most respondents )54.6%( recommended colistin-based combination therapy for the treatment of VAP due to XDR AB. Although we did not address the downsides of using monotherapy in our study, heteroresistance, rapid selection for resistance, toxicity, and lower efficacy were often common barriers for this treatment. 10 Although synergism with combination therapy has been showing in vitro laboratory studies, clinical data has revealed conflicting results. A retrospective study of 27 tertiary-care centers in Turkey that included 250 patients with XDR AB infection showed that microbiological eradication and in-hospital survival rates were significantly higher with colistin-based combination therapy. 11 In another retrospective study, Kalin et al 12 showed a non-significant improvement in cure and bacteriological clearance rates in patients treated with a combination of colistin and sulbactam compared with those treated with IV Saudi Med J 2015; Vol. 36 )12( www.smj.org.sa colistin monotherapy. Although carbapenems were the preferred add-on agents in our survey, a previous study 11 showed these agents did not improve 14-day mortality or clinical and microbiological clearance when used in combination therapy. Furthermore, in a recent retrospective study by Khawcharoenporn et al, 13 a 28-day mortality and hospital length of stay were not significantly different among colistin-based regimens in a cohort of 236 patients with XDR AB pneumonia. The optimal duration for VAP treatment caused by AB is controversial. In our study, more than 60% of respondents preferred to administer a 14-day course. However, a systematic review favored a shorter antibiotic course )7-days( for treating VAP compared with a longer course )10-days(. 14 However, the recurrence rate was higher in the group of patients who were infected with non-fermenting Gram-negative bacilli and received the shorter course.
14 This data demonstrates variation in practice, and reflects the need for studies examining the effects of treatment duration on outcomes in patients with VAP due to MDR gram-negative bacteria.
A recent study 15 examining the optimal dosing of colistin showed that giving a 9 mu loading dose of colistin methanesulfonate followed by 4.5 mu every 12 hours resulted in early achievement of therapeutic concentrations of colistin in the blood of patients with normal kidney function. 15 In our study, there were significant differences in the preferred doses. Most of the respondents opted for 2 mu every 8 hours; however, most of the consultants believed that a loading dose was essential. The rationale for this approach is that a steady state therapeutic concentration of colistin is reached after several days if a loading dose is not given, which will cause a delay in cure rate, and a recent study 16 suggested that a loading dose with a high dose extended interval colistin methanesulfonate regime had a high clinical cure rate.
More than 50% of respondents preferred to add IV colistin empirically for the treatment of late-onset VAP with septic shock despite broad-spectrum antibiotics. The study by Kumar et al 17 revealed that delayed antibiotic therapy was associated with increased mortality in patients with septic shock. The choice of antibiotics in patients with VAP and septic shock depends on local epidemiology, risk factors, recent hospitalization, antibiotics use, previous colonisation, and infection with resistant strains. 18 Rello et al 19 demonstrated that the empirical use of colistin and meropenem decreased length of stay in the ICU in pneumonia patients who had a baseline AB prevalence more than 10%. Given the high prevalence of XDR AB infection, or colonization in most ICUs in Saudi Arabia, adding IV colistin is appropriate in situations with late-onset VAP with septic shock. 20 Most of clinicians )80%( in our survey recommended treating ICU patients with VAT, but the administration route, and the agents to be used varied among respondents. Treatment of VAT remains a topic of debate in the current literature, 21 and 2 randomized controlled trials )RCTs( have addressed this issue. The first RCT 22 demonstrated that treated patients had lower mortality and fewer days on mechanical ventilation compared with untreated patients, and the second RCT also showed a shorter duration of mechanical ventilation in the treatment group. 23 Interestingly, 36 participants )19.7%( in our study supported the use of nebulized colistin alone, which has been shown to reduce the progression rate of VAP, development of resistance, and the need for systemic antibiotic use in a small study. 23 However, the effect of nebulized colistin, either alone or in combination with other antibiotics, for the treatment of VAP or VAT is controversial. Korbila et al 24 described that a combination of nebulized and IV colistin resulted in a better cure rate compared with IV colistin alone in 121 patients with VAP without a significant change in mortality, and similar findings have been shown in a recent case-control study of 208 patients with VAP. 25 A recent RCT 26 revealed that patients with VAP caused by Gram-negative bacteria showed no clinical improvement in response to adjunctive nebulized colistin therapy compared with patients who were only given systemic antibiotics. In addition to local side effects of colistin nebulization, such as pneumonitis, bronchospasm, and respiratory failure, development of drug resistance is another concern among clinicians. A recent study 27 demonstrated that 4 out of 12 patients receiving colistin nebulization developed resistance to the antibiotic. However, more research in a wider range of patients is essential to elucidate this phenomenon of drug resistance. Since there is no clear data on treatment of VAP and VAT caused by XDR AB, we hypothesized that the workplace, specialty, job title, and clinical experience of the healthcare practitioner would influence the dose, duration, and type of antibiotics. However, we found that these factors had little effect on most responses, likely due to the absence of clear recommendations and guidelines.
Study limitations. First, most of the participants were from Riyadh, thus limiting the generalizability of our results. Second, most of respondents were in the ICU field and few ID specialists responded, indicating we were unable to survey all physician stakeholders. Third, physicians were not asked on which guidelines they based their choices. Fourth, the self-reported practices in our survey may not reflect the actual practice of respondents )inherent in all surveys(. We adopted a systemic approach in the development of this survey and had a good response rate of 68%.
In conclusion, this study revealed that clinicians of different specialties and length of experience varied widely in their treatment of VAP and VAT caused by XDR AB. These differences are likely related to the lack of high-quality evidence and clinical practice guidelines, as well as the conflicting results of the available studies. Given the increasing incidence of VAP and VAT caused by XDR gram-negative bacteria and the high mortality rate associated with these infections, large multicenter RCTs on the benefits of colistin-based combination therapy versus colistin monotherapy, the value of colistin loading dose versus non loading dose, the value of lower dose versus higher maintenance colistin dose and so on, are warranted to help guide the clinical practice and effectively treat these infections.
